Published in J Immunol on July 23, 2014
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood (2015) 0.97
Hepatic Stellate Cells Inhibit T Cells through Active TGF-β1 from a Cell Surface-Bound Latent TGF-β1/GARP Complex. J Immunol (2015) 0.88
Tolerance and immune suppression in the tumor microenvironment. Cell Immunol (2015) 0.84
The Role and Potential Therapeutic Application of Myeloid-Derived Suppressor Cells in Allo- and Autoimmunity. Mediators Inflamm (2015) 0.77
Adipose-derived mesenchymal stromal cells modulate experimental autoimmune arthritis by inducing an early regulatory innate cell signature. Immun Inflamm Dis (2016) 0.76
Hepatic immune tolerance induced by hepatic stellate cells. World J Gastroenterol (2015) 0.76
C-C Chemokine Receptor type 2 (CCR2)-Dependent Migration of Myeloid-Derived Suppressor Cells in Protection of Islet Transplants. Transplantation (2016) 0.75
Animal models of myasthenia gravis: utility and limitations. Int J Gen Med (2016) 0.75
Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β. Virology (2016) 0.75
Molecular mimicry and clonal deletion: A fresh look. J Theor Biol (2014) 0.75
Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1. J Immunol (2016) 0.75
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 3.41
Myasthenia gravis: past, present, and future. J Clin Invest (2006) 3.06
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med (2009) 2.68
Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat Immunol (2002) 2.64
NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins (1994) 2.60
Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat (2002) 2.36
Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. J Leukoc Biol (2010) 2.22
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat Med (2002) 1.61
The T-cell-independent immune response to the hapten NP uses a large repertoire of heavy chain genes. Cell (1985) 1.59
Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res (1987) 1.59
Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology (2011) 1.44
Effects of the new arginase inhibitor N(omega)-hydroxy-nor-L-arginine on NO synthase activity in murine macrophages. Nitric Oxide (1999) 1.38
In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol (2011) 1.37
NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des (2006) 1.31
Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest (2002) 1.31
Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity (2010) 1.11
Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J Natl Cancer Inst (1984) 1.05
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
Regulation of human B cell proliferation by prostaglandin E2. J Immunol (1984) 1.01
B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol (2008) 0.98
Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med (2008) 0.95
Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunol Immunopathol (1985) 0.94
Nitric oxide synthase inhibitors: amino acids. Methods Enzymol (1996) 0.92
The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells. Blood (2013) 0.92
GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol (2011) 0.90
Editorial: PGE2-producing MDSC: a role in tumor progression? J Leukoc Biol (2010) 0.87
Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency. J Virol (2012) 0.87
Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve (2012) 0.86
T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol (2009) 0.84
Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol (2011) 0.83
FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun (1997) 0.83
Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr (2003) 0.80
Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J Neuroimmunol (2009) 0.77
C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol (2008) 0.77